U.S. Patent Office Confirms Second of Four Viread(R) Patents
June 02 2008 - 12:38PM
Business Wire
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S.
Patent & Trademark Office (PTO) has completed the second of
four reexamination proceedings and has confirmed the patentability
of U.S. Patent No. 5,922,695, which covers the composition of
matter for Viread (tenofovir disoproxil fumarate). On May 20,
Gilead announced that the U.S. PTO confirmed the patentability of
U.S. Patent No. 6,043,230. The four U.S. PTO review proceedings
were initiated July 2007 in response to a challenge issued by the
Public Patent Foundation (PUBPAT) in March 2007 for U.S. Patents
No. 5,922,695; 5,977,089; 5,935,946; and 6,043,230. In its request
for the reexaminations, PUBPAT claimed that prior art existed that
would have impacted the issuance of the original patents. �Of the
four patents originally under PTO review, this composition of
matter patent is the most integral to Viread�s novel exclusivity,�
said Gregg Alton, Senior Vice President and General Counsel. �We
are pleased with the PTO�s swift analyses and actions, which have
confirmed the strength of our patent position.� About Gilead
Sciences Gilead Sciences is a biopharmaceutical company that
discovers, develops and commercializes innovative therapeutics in
areas of unmet medical need. The company�s mission is to advance
the care of patients suffering from life-threatening diseases
worldwide. Headquartered in Foster City, California, Gilead has
operations in North America, Europe and Australia. Forward-Looking
Statement This press release includes forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act
of 1995, that are subject to risks, uncertainties and other
factors, including uncertainty related to the expected timing of
the U.S. PTO�s ruling on the remaining two Viread patents, the risk
that the U.S. PTO may narrow or invalidate some or all of the
original claims in such patents and the risk of the ultimate
enforceability of this patent should it be challenged in a court of
law. These risks, uncertainties and other factors could cause
actual results to differ materially from those referred to in the
forward-looking statements. The reader is cautioned not to rely on
these forward-looking statements. These and other risks are
described in detail in Gilead's Annual Report on Form 10-K for the
year ended December 31, 2007 and Quarterly Report on Form 10-Q for
the quarter ended March 31, 2008, as filed with the U.S. Securities
and Exchange Commission. All forward-looking statements are based
on information currently available to Gilead, and Gilead assumes no
obligation to update any such forward-looking statements. Viread is
a registered trademark of Gilead Sciences, Inc. For more
information on Gilead, please call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235) or visit
www.gilead.com.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Jul 2023 to Jul 2024